Pliant Therapeutics Inc
$ 1.33
2.31%
17 Apr - close price
- Market Cap 80,489,000 USD
- Current Price $ 1.33
- High / Low $ 1.38 / 1.30
- Stock P/E N/A
- Book Value 2.95
- EPS -2.43
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.30 %
- ROE -0.62 %
- 52 Week High 1.95
- 52 Week Low 1.09
About
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and markets new therapies for the treatment of fibrosis and related diseases in the United States. The company is headquartered in South San Francisco, California.
Analyst Target Price
$2.67
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-03 | 2025-11-06 | 2025-08-07 | 2025-05-05 | 2025-02-25 | 2024-11-07 | 2024-08-07 | 2024-05-06 | 2024-02-27 | 2023-11-09 | 2023-08-09 | 2023-05-09 |
| Reported EPS | -0.3539 | -0.43 | -0.71 | -0.92 | -0.82 | -0.95 | -0.92 | -0.78 | -0.69 | -0.7 | -0.7 | -0.67 |
| Estimated EPS | -0.4162 | -0.56 | -0.6595 | -0.7469 | -0.9552 | -0.97 | -0.85 | -0.77 | -0.81 | -0.77 | -0.71 | -0.67 |
| Surprise | 0.0623 | 0.13 | -0.0505 | -0.1731 | 0.1352 | 0.02 | -0.07 | -0.01 | 0.12 | 0.07 | 0.01 | 0 |
| Surprise Percentage | 14.9688% | 23.2143% | -7.6573% | -23.1758% | 14.1541% | 2.0619% | -8.2353% | -1.2987% | 14.8148% | 9.0909% | 1.4085% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.36 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PLRX
2026-04-15 20:10:35
Pliant Therapeutics, Inc. (NASDAQ:PLRX) has received a consensus "Reduce" rating from analysts, with an average 12-month target price of $3.00. The company's CEO recently sold shares, reducing his stake, while several institutional investors have adjusted their holdings. PLRX stock is currently trading near $1.30, and analysts anticipate a full-year EPS of -3.64.
2026-04-14 08:09:55
Pliant Therapeutics (NASDAQ:PLRX) shares rose 1.6% on Monday, trading at $1.30 with lower-than-average volume. Despite beating quarterly EPS estimates, the company faces weak Wall Street sentiment, with a "Reduce" consensus rating and an average price target of $3.00, reflecting recent price target cuts and mixed analyst ratings. Insider selling by the CEO and high institutional ownership are also noted for the clinical-stage biopharma focused on fibrotic diseases.
2026-04-07 09:40:00
Pliant Therapeutics, Inc. (PLRX) has filed an EFFECT S-3 form with the SEC, which became effective on April 6, 2026, at 4:15 P.M. The filing indicates a neutrality in both its impact and sentiment. This S-3 shelf registration allows the company to offer securities in the future, providing financial flexibility.
2026-04-04 14:39:47
Pliant Therapeutics Inc (PLRX) is currently considered to be in the "Fair zone" based on its forward P/S ratio of 33.43 compared to its five-year average. The fair price for PLRX is estimated between $0.48 to $1.64 using a relative valuation method. While its P/S ratio is 112.58% above the industry average, this premium is deemed unsustainable given its current revenue growth.
2026-04-03 08:39:43
Pliant Therapeutics has initiated a new At-The-Market (ATM) equity program, allowing the company to sell up to $50 million of its common stock through Leerink Partners LLC. This new agreement replaces a previous one with Cantor Fitzgerald & Co., which was terminated without any shares sold or penalties incurred. Spark, TipRanks’ AI Analyst, rates PLRX as Neutral due to weak financial performance, including ongoing losses and negative free cash flow.
2026-03-31 02:38:57
Pliant Therapeutics (PLRX) has initiated a new at-the-market offering program, enabling it to sell up to $50.0 million in common stock through Leerink Partners. Concurrently, the company terminated its previous sales agreement from July 2, 2021, with Cantor Fitzgerald, with no shares sold under that prior agreement and no associated termination penalties.
